X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (90) 90
male (80) 80
index medicus (79) 79
female (71) 71
middle aged (67) 67
aged (64) 64
electricity (64) 64
oncology (53) 53
basic electric elements (51) 51
electric solid state devices not otherwise provided for (51) 51
semiconductor devices (51) 51
adult (48) 48
chemotherapy (43) 43
performing operations (41) 41
transporting (41) 41
retrospective studies (35) 35
cancer (32) 32
medicine & public health (29) 29
physics (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (25) 25
general tagging of cross-sectional technologies spanning over several sections of the ipc (25) 25
general tagging of new technological developments (25) 25
surgical oncology (25) 25
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (25) 25
treatment outcome (23) 23
gastroenterology & hepatology (22) 22
pancreatic cancer (21) 21
technical subjects covered by former us classification (21) 21
technical subjects covered by former uspc (21) 21
animals (19) 19
analysis (18) 18
cinematography (18) 18
drug combinations (18) 18
electrography (18) 18
holography (18) 18
photography (18) 18
care and treatment (16) 16
disease-free survival (16) 16
japan (16) 16
oxaliplatin (16) 16
pancreatic neoplasms - drug therapy (16) 16
stomach neoplasms - drug therapy (16) 16
gemcitabine (15) 15
radiotherapy (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (14) 14
diagnosis (14) 14
fluorouracil (14) 14
gastric cancer (14) 14
s-1 (14) 14
stomach neoplasms - pathology (14) 14
5-fluorouracil (13) 13
deoxycytidine - analogs & derivatives (13) 13
gastroenterology (13) 13
patients (13) 13
research (13) 13
apparatus specially adapted therefor (12) 12
applying liquids or other fluent materials to surfaces, in general (12) 12
cancer research (12) 12
cisplatin (12) 12
drug administration schedule (12) 12
irinotecan (12) 12
layered products (12) 12
layered products, i.e. products built-up of strata of flat ornon-flat, e.g. cellular or honeycomb, form (12) 12
materials therefor (12) 12
metastasis (12) 12
originals therefor (12) 12
pancreatic neoplasms - pathology (12) 12
photomechanical production of textured or patterned surfaces,e.g. for printing, for processing of semiconductordevices (12) 12
prognosis (12) 12
spraying or atomising in general (12) 12
stomach cancer (12) 12
survival analysis (12) 12
adenocarcinoma - drug therapy (11) 11
internal medicine (11) 11
pathology (11) 11
rats (11) 11
risk factors (11) 11
survival rate (11) 11
trial (11) 11
camptothecin - administration & dosage (10) 10
camptothecin - analogs & derivatives (10) 10
cisplatin - administration & dosage (10) 10
japan - epidemiology (10) 10
survival (10) 10
aged, 80 and over (9) 9
antineoplastic agents - administration & dosage (9) 9
cancer patients (9) 9
cancer therapies (9) 9
carcinoma (9) 9
deoxycytidine - administration & dosage (9) 9
fluorouracil - administration & dosage (9) 9
kaplan-meier estimate (9) 9
neoplasm staging (9) 9
rats, wistar (9) 9
supportive care (9) 9
surgery (9) 9
therapy (9) 9
young adult (9) 9
adenocarcinoma - pathology (8) 8
allergy (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2015, Volume 26, p. vii9
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2017, Volume 35, Issue 4, pp. 499 - 508
Background Lanreotide is a long-acting somatostatin analog with demonstrated efficacy against enteropancreatic neuroendocrine tumor (NET) in the phase III... 
Medicine & Public Health | Lanreotide | Oncology | Phase II | Pharmacology/Toxicology | Neuroendocrine tumor | Japanese | Somatostatin analog | ONCOLOGY | ANALOGS | PHARMACOLOGY & PHARMACY | SOMATOSTATIN RECEPTORS | Pancreatic Neoplasms - metabolism | Somatostatin - adverse effects | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Pancreatic Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Gastrointestinal Neoplasms - metabolism | Somatostatin - analogs & derivatives | Gels | Neuroendocrine Tumors - metabolism | Kaplan-Meier Estimate | Treatment Outcome | Somatostatin - pharmacokinetics | Peptides, Cyclic - pharmacokinetics | Peptides, Cyclic - blood | Disease-Free Survival | Asian Continental Ancestry Group | Somatostatin - blood | Antineoplastic Agents - blood | Neuroendocrine Tumors - drug therapy | Peptides, Cyclic - therapeutic use | Aged | Somatostatin - therapeutic use | Peptides, Cyclic - adverse effects | Complications and side effects | Dosage and administration | Somatostatin | Research | Fas antigen | Midgut | Hindgut | Diabetes mellitus | Pharmacology | Injection | Patients | Survival | Metastases | Confidence intervals | Studies | Lungs | Multiple endocrine neoplasia | Safety | Feces | Pancreas | Pharmacokinetics | Foregut | Tumors | Neuroendocrine tumors | Phase II Studies
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2014, Volume 25, p. v14
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10041, pp. 248 - 257
Journal Article
Diabetes, ISSN 0012-1797, 02/2014, Volume 63, Issue 2, pp. 605 - 618
Journal Article
Suizo, ISSN 0913-0071, 2018, Volume 33, Issue 1, pp. 37 - 47
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2016, Volume 11, Issue 3, p. e0148926
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 07/2015, Volume 106, Issue 7, pp. 883 - 890
Gemcitabine is a key drug for the treatment of pancreatic cancer; however, with its limitation in clinical benefits, the development of another potent... 
phase II/III | elpamotide | Advanced pancreatic cancer | peptide vaccine | immunotherapy | Peptide vaccine | Elpamotide | Immunotherapy | Phase II/III | PLUS GEMCITABINE | 1ST-LINE TREATMENT | ENDOTHELIAL-GROWTH-FACTOR | FACTOR RECEPTOR-2 | EPITOPE-PEPTIDES | METASTATIC COLORECTAL-CANCER | CELL LUNG-CANCER | ONCOLOGY | POOR-PROGNOSIS | III TRIAL | COOPERATIVE-ONCOLOGY-GROUP | Adenocarcinoma - pathology | Carcinoma, Adenosquamous - pathology | Double-Blind Method | Cancer Vaccines - administration & dosage | Deoxycytidine - administration & dosage | Humans | Middle Aged | Pancreatic Neoplasms - pathology | Peptide Fragments - administration & dosage | Kaplan-Meier Estimate | Carcinoma, Adenosquamous - drug therapy | Male | Treatment Outcome | Adenocarcinoma - drug therapy | Pancreatic Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Adenosquamous - mortality | Adult | Female | Aged | Pancreatic Neoplasms - mortality | Vascular Endothelial Growth Factor Receptor-2 - administration & dosage | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Statistical analysis | Gemcitabine | Peptides | Toxicity | Clinical trials | Metastasis | Radiation therapy | Cancer therapies | Survival | Patients | Blood | Metastases | Angiogenesis | Chemotherapy | Pancreatic cancer | Medical prognosis | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor | Index Medicus | phase II | III | Original
Journal Article